The DOI matches its Crossref record.
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Open accessAbstract
Purpose: Chronic myeloid leukemia (CML) management changed dramatically with the development of imatinib mesylate (IM), the first tyrosine kinase inhibitor targeting the BCR-ABL1 oncoprotein. In Sweden, the drug was approved in November 2001. We report relative survival (RS) of patients with CML diagnosed during a 36-year period. Patients and Methods: Using data from the population-based Swedish Cancer Registry and population life tables, we estimated RS for all patients diagnosed with CML from 1973 to 2008 (n = 3,173; 1,796 males and 1,377 females; median age, 62 years). Patients were categorized into five age groups and five calendar periods, the last being 2001 to 2008. Information on use of upfront IM was collected from the Swedish CML registry. Results: Relative survival improved with each calendar period, with the greatest improvement between 1994-2000 and 2001-2008. Five-year cumulative relative survival ratios (95% Cls) were 0.21 (0.17 to 0.24) for patients diagnosed 1973-1979, 0.54 (0.50 to 0.58) for 1994-2000, and 0.80 (0.75 to 0.83) for 2001-2008. This improvement was confined to patients younger than 79 years of age. Five-year RSRs for patients diagnosed from 2001 to 2008 were 0.91 (95% CI, 0.85 to 0.94) and 0.25 (95% CI, 0.10 to 0.47) for patients younger than 50 and older than 79 years, respectively. Men had inferior outcome. Upfront overall use of IM increased from 40% (2002) to 84% (2006). Only 18% of patients older than 80 years of age received IM as first-line therapy. Conclusion: This large population-based study shows a major improvement in outcome of patients with CML up to 79 years of age diagnosed from 2001 to 2008, mainly caused by an increasing use of IM. The elderly still have poorer outcome, partly because of a limited use of IM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Self-citationLeukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Kantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S., Kadia, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 334
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia
Han, S. H., Korm, S., Han, Y. G., Choi, S.-Y., Kim, S.-H., Chung, H. J., Park, K., Kim, J.-Y., Myung, K., Lee, J.-Y., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596492 · Cited by 53
Farmer, S., Horváth‐Puhó, E., Vestergaard, H., Hermann, A. P., & Frederiksen, H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12581 · Cited by 45
Metadata
- Authors
- Björkholm, M., Ohm, L., Eloranta, S., Derolf, Å., Hultcrantz, M., Sjöberg, J., Andersson, T., Höglund, M., Richter, J., Landgren, O., Kristinsson, S. Y., & Dickman, P. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-20
- Volume
- 29
- Issue
- 18
- Pages
- 2514-2520
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164168439
- Cited by
- 211
- References
- 0
- FWCI
- 15.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. https://app.cochat.ai/papers/10.1200/jco.2011.34.7146
- The paper
- Björkholm, M., Ohm, L., Eloranta, S., Derolf, Å., Hultcrantz, M., Sjöberg, J., Andersson, T., Höglund, M., Richter, J., Landgren, O., Kristinsson, S. Y., & Dickman, P. W. (2011). Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.34.7146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.